Autism: Where Genetics Meets the Immune System / Antonio M. PERSICO in Autism Research and Treatment, (July 2012)  

Public ISBD [article]  inAutism Research and Treatment > (July 2012) . - 2 p. Titre : Autism: Where Genetics Meets the Immune System Type de document : Texte imprimé et/ou numérique Auteurs : Antonio M. PERSICO, Auteur ; Judy VAN DE WATER, Auteur ; Carlos A. PARDO, Auteur Année de publication : 2012 Article en page(s) : 2 p. Langues : Anglais (eng) Mots-clés : Immunologie Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1155/2012/486359 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181 [article] Autism: Where Genetics Meets the Immune System [Texte imprimé et/ou numérique] / Antonio M. PERSICO, Auteur ; Judy VAN DE WATER, Auteur ; Carlos A. PARDO, Auteur . - 2012 . - 2 p. Langues : Anglais (eng) in Autism Research and Treatment > (July 2012) . - 2 p. Mots-clés : Immunologie Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1155/2012/486359 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181

A pilot open-label trial of minocycline in patients with autism and regressive features / Carlos A. PARDO in Journal of Neurodevelopmental Disorders, 5-1 (December 2013)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 5-1 (December 2013) . - p.9 Titre : A pilot open-label trial of minocycline in patients with autism and regressive features Type de document : Texte imprimé et/ou numérique Auteurs : Carlos A. PARDO, Auteur ; A. BUCKLEY, Auteur ; A. THURM, Auteur ; L. C. LEE, Auteur ; A. AZHAGIRI, Auteur ; D. M. NEVILLE, Auteur ; Susan E. SWEDO, Auteur Article en page(s) : p.9 Langues : Anglais (eng) Mots-clés : Autism  Bdnf  Chemokines  Clinical trial  Cytokines  Metalloproteinases  Microglia  Minocycline  Neuroinflammation  Neurotrophins Index. décimale : PER Périodiques Résumé : BACKGROUND: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression. METHODS: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation. RESULTS: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and alpha-2 macroglobulin (alpha-2 M), was also significantly lower (P = 0.028) while the mature BDNF/alpha-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-alpha, CD40L, IL-6, IFN-gamma and IL-1beta when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline. CONCLUSIONS: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration. TRIAL REGISTRATION: NCT00409747. En ligne : http://dx.doi.org/10.1186/1866-1955-5-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=345 [article] A pilot open-label trial of minocycline in patients with autism and regressive features [Texte imprimé et/ou numérique] / Carlos A. PARDO, Auteur ; A. BUCKLEY, Auteur ; A. THURM, Auteur ; L. C. LEE, Auteur ; A. AZHAGIRI, Auteur ; D. M. NEVILLE, Auteur ; Susan E. SWEDO, Auteur . - p.9. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 5-1 (December 2013) . - p.9 Mots-clés : Autism  Bdnf  Chemokines  Clinical trial  Cytokines  Metalloproteinases  Microglia  Minocycline  Neuroinflammation  Neurotrophins Index. décimale : PER Périodiques Résumé : BACKGROUND: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression. METHODS: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation. RESULTS: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and alpha-2 macroglobulin (alpha-2 M), was also significantly lower (P = 0.028) while the mature BDNF/alpha-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-alpha, CD40L, IL-6, IFN-gamma and IL-1beta when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline. CONCLUSIONS: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration. TRIAL REGISTRATION: NCT00409747. En ligne : http://dx.doi.org/10.1186/1866-1955-5-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=345

Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study / Carlos A. PARDO in Molecular Autism, 8 (2017)  

Public ISBD [article]  inMolecular Autism > 8 (2017) . - 1p. Titre : Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study Type de document : Texte imprimé et/ou numérique Auteurs : Carlos A. PARDO, Auteur ; C. A. FARMER, Auteur ; A. THURM, Auteur ; F. M. SHEBL, Auteur ; J. ILIEVA, Auteur ; S. KALRA, Auteur ; Susan E. SWEDO, Auteur Article en page(s) : 1p. Langues : Anglais (eng) Mots-clés : Autistic Disorder/*immunology/metabolism  Chemokines/*blood/*cerebrospinal fluid  Child  Child, Preschool  Cytokines/*blood/*cerebrospinal fluid  Female  Humans  Intercellular Signaling Peptides and Proteins/blood/cerebrospinal fluid  Longitudinal Studies  Male  Prospective Studies  *Autism  *Csf  *Chemokine  *Cytokine  *Growth factor  *Immune Index. décimale : PER Périodiques Résumé : BACKGROUND: The causes of autism likely involve genetic and environmental factors that influence neurobiological changes and the neurological and behavioral features of the disorder. Immune factors and inflammation are hypothesized pathogenic influences, but have not been examined longitudinally. METHODS: In a cohort of 104 participants with autism, we performed an assessment of immune mediators such as cytokines, chemokines, or growth factors in serum and cerebrospinal fluid (n = 67) to determine potential influences of such mediators in autism. RESULTS: As compared with 54 typically developing controls, we found no evidence of differences in the blood profile of immune mediators supportive of active systemic inflammation mechanisms in participants with autism. Some modulators of immune function (e.g., EGF and soluble CD40 ligand) were increased in the autism group; however, no evidence of group differences in traditional markers of active inflammation (e.g., IL-6, TNFalpha, IL-1beta) were observed in the serum. Further, within-subject stability (measured by estimated intraclass correlations) of most analytes was low, indicating that a single measurement is not a reliable prospective indicator of concentration for most analytes. Additionally, in participants with autism, there was little correspondence between the blood and CSF profiles of cytokines, chemokines, and growth factors, suggesting that peripheral markers may not optimally reflect the immune status of the central nervous system. Although the relatively high fraction of intrathecal production of selected chemokines involved in monocyte/microglia function may suggest a possible relationship with the homeostatic role of microglia, control data are needed for further interpretation of its relevance in autism. CONCLUSIONS: These longitudinal observations fail to provide support for the hypothesized role of disturbances in the expression of circulating cytokines and chemokines as an indicator of systemic inflammation in autism. ClinicalTrials.gov, NCT00298246. En ligne : http://dx.doi.org/10.1186/s13229-016-0115-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=330 [article] Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal study [Texte imprimé et/ou numérique] / Carlos A. PARDO, Auteur ; C. A. FARMER, Auteur ; A. THURM, Auteur ; F. M. SHEBL, Auteur ; J. ILIEVA, Auteur ; S. KALRA, Auteur ; Susan E. SWEDO, Auteur . - 1p. Langues : Anglais (eng) in Molecular Autism > 8 (2017) . - 1p. Mots-clés : Autistic Disorder/*immunology/metabolism  Chemokines/*blood/*cerebrospinal fluid  Child  Child, Preschool  Cytokines/*blood/*cerebrospinal fluid  Female  Humans  Intercellular Signaling Peptides and Proteins/blood/cerebrospinal fluid  Longitudinal Studies  Male  Prospective Studies  *Autism  *Csf  *Chemokine  *Cytokine  *Growth factor  *Immune Index. décimale : PER Périodiques Résumé : BACKGROUND: The causes of autism likely involve genetic and environmental factors that influence neurobiological changes and the neurological and behavioral features of the disorder. Immune factors and inflammation are hypothesized pathogenic influences, but have not been examined longitudinally. METHODS: In a cohort of 104 participants with autism, we performed an assessment of immune mediators such as cytokines, chemokines, or growth factors in serum and cerebrospinal fluid (n = 67) to determine potential influences of such mediators in autism. RESULTS: As compared with 54 typically developing controls, we found no evidence of differences in the blood profile of immune mediators supportive of active systemic inflammation mechanisms in participants with autism. Some modulators of immune function (e.g., EGF and soluble CD40 ligand) were increased in the autism group; however, no evidence of group differences in traditional markers of active inflammation (e.g., IL-6, TNFalpha, IL-1beta) were observed in the serum. Further, within-subject stability (measured by estimated intraclass correlations) of most analytes was low, indicating that a single measurement is not a reliable prospective indicator of concentration for most analytes. Additionally, in participants with autism, there was little correspondence between the blood and CSF profiles of cytokines, chemokines, and growth factors, suggesting that peripheral markers may not optimally reflect the immune status of the central nervous system. Although the relatively high fraction of intrathecal production of selected chemokines involved in monocyte/microglia function may suggest a possible relationship with the homeostatic role of microglia, control data are needed for further interpretation of its relevance in autism. CONCLUSIONS: These longitudinal observations fail to provide support for the hypothesized role of disturbances in the expression of circulating cytokines and chemokines as an indicator of systemic inflammation in autism. ClinicalTrials.gov, NCT00298246. En ligne : http://dx.doi.org/10.1186/s13229-016-0115-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=330

Using Tic-Tac software to reduce anxiety-related behaviour in adults with autism and learning difficulties during waiting periods: A pilot study / Cristina CAMPILLO in Autism, 18-3 (April 2014)  

Public ISBD [article]  inAutism > 18-3 (April 2014) . - p.264-271 Titre : Using Tic-Tac software to reduce anxiety-related behaviour in adults with autism and learning difficulties during waiting periods: A pilot study Type de document : Texte imprimé et/ou numérique Auteurs : Cristina CAMPILLO, Auteur ; Gerardo HERRERA, Auteur ; Conchi REMIREZ DE GANUZA, Auteur ; José L. CUESTA, Auteur ; Raquel ABELLÁN, Auteur ; Arturo CAMPOS, Auteur ; Ignacio NAVARRO, Auteur ; Javier SEVILLA, Auteur ; Carlos A. PARDO, Auteur ; Fabián AMATI, Auteur Article en page(s) : p.264-271 Langues : Anglais (eng) Mots-clés : anxiety-related behaviours  autism  technology  time perception Index. décimale : PER Périodiques Résumé : Deficits in the perception of time and processing of changes across time are commonly observed in individuals with autism. This pilot study evaluated the efficacy of the use of the software tool Tic-Tac, designed to make time visual, in three adults with autism and learning difficulties. This research focused on applying the tool in waiting situations where the participants exhibited anxiety-related behaviour. The intervention followed a baseline and intervention (AB) design, and a partial interval recording procedure was used to code the presence of stereotypes, nervous utterances, wandering or other examples of nervousness during the selected waiting situations. The results showed that the use of Tic-Tac resulted in lower levels of anxiety-related behaviour in all three participants, compared to the baseline, suggesting that this software may be an effective technology for helping people with autism with organisation and predictability during waiting periods. The results are discussed in terms of limitations and implications for further study. En ligne : http://dx.doi.org/10.1177/1362361312472067 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=229 [article] Using Tic-Tac software to reduce anxiety-related behaviour in adults with autism and learning difficulties during waiting periods: A pilot study [Texte imprimé et/ou numérique] / Cristina CAMPILLO, Auteur ; Gerardo HERRERA, Auteur ; Conchi REMIREZ DE GANUZA, Auteur ; José L. CUESTA, Auteur ; Raquel ABELLÁN, Auteur ; Arturo CAMPOS, Auteur ; Ignacio NAVARRO, Auteur ; Javier SEVILLA, Auteur ; Carlos A. PARDO, Auteur ; Fabián AMATI, Auteur . - p.264-271. Langues : Anglais (eng) in Autism > 18-3 (April 2014) . - p.264-271 Mots-clés : anxiety-related behaviours  autism  technology  time perception Index. décimale : PER Périodiques Résumé : Deficits in the perception of time and processing of changes across time are commonly observed in individuals with autism. This pilot study evaluated the efficacy of the use of the software tool Tic-Tac, designed to make time visual, in three adults with autism and learning difficulties. This research focused on applying the tool in waiting situations where the participants exhibited anxiety-related behaviour. The intervention followed a baseline and intervention (AB) design, and a partial interval recording procedure was used to code the presence of stereotypes, nervous utterances, wandering or other examples of nervousness during the selected waiting situations. The results showed that the use of Tic-Tac resulted in lower levels of anxiety-related behaviour in all three participants, compared to the baseline, suggesting that this software may be an effective technology for helping people with autism with organisation and predictability during waiting periods. The results are discussed in terms of limitations and implications for further study. En ligne : http://dx.doi.org/10.1177/1362361312472067 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=229

---

1 (1 - 4 / 4)